[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350740-105":59,"doc-detail-350740-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","clip2met-fusion-identifies-a-molecularly-distinct-glioneuronal-tumor-case-report","CLIP2::MET fusion identifies a molecularly distinct glioneuronal tumor - Case report","","Glioneuronal tumors are rare central nervous system neoplasms with heterogeneous clinical, histological, and molecular characteristics, making diagnosis and classification difficult due to overlapping morphology and limited defining alterations. A 19-year-old female with a right frontal lobe lesion initially suspected as low-grade glioma showed mixed glial and neuronal histology and low proliferation. Conventional testing was negative for IDH1/IDH2 and BRAF mutations. DNA methylation profiling did not match known CNS classes and clustered closest to low-grade glioma/ganglioglioma. Next-generation RNA sequencing revealed a CLIP2::MET fusion as the sole pathogenic alteration, supporting a distinct MET-driven molecular subset relevant to precision oncology and actionable therapy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/clip2met-fusion-identifies-a-molecularly-distinct-glioneuronal-tumor-case-report/350740/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/clip2met-fusion-identifies-a-molecularly-distinct-glioneuronal-tumor-case-report/350740.png","ImageObject",300,407,{"name":92,"@type":93},"mieayamfan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-17","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is diagnosis of glioneuronal tumors challenging?","Question",{"text":112,"@type":113},"Diagnosis and classification are difficult because these tumors show overlapping morphology and often lack defining molecular alterations.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What molecular finding was identified in this case?",{"text":117,"@type":113},"Comprehensive RNA sequencing detected a CLIP2::MET fusion as the sole pathogenic alteration.",{"name":119,"@type":110,"acceptedAnswer":120},"How did methylation and standard testing guide the case classification?",{"text":121,"@type":113},"Standard testing was negative for IDH1/IDH2 and BRAF mutations, and DNA methylation profiling did not match known CNS classes, clustering closest to low-grade glioma/ganglioglioma.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},350740,1790180845,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},962090893677,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Fares et al. Discover Oncology (2026) 17:1251 Discover Oncology  \n[https://doi.org/10.1007/s12672-026-05421-2](https://doi.org/10.1007/s12672-026-05421-2)  \nCASE REPORT Open Access  \nCLIP2::MET fusion identifies a molecularly distinct glioneuronal tumor  \nJawad Fares 1,2*, Jared T. Ahrendsen3, HarrshavasanT. Congivaram 1,2, Lucas Santana-Santos3, Daniel Oyon1,2, Karan Dixit4, Mark W. Youngblood 1,2 and James P. Chandler 1,2*  \n*Correspondence:  \nJawad Fares [jawad.fares@northwestern.edu](jawad.fares@northwestern.edu)[ ](jawad.fares@northwestern.edu)James P. Chandler [jchandle@nm.org](jchandle@nm.org)  \nFull list of author information is available at the end of the article  \nAbstract  \nGlioneuronal tumors are rare central nervous system (CNS) neoplasms with heterogeneous clinical, histological, and molecular features. Diagnosis and classification are often challenging due to overlapping morphology and limited defining alterations. Here, we present a 19-year-old female with a right frontal lobe glioneuronal tumor, initially suspected to be a low-grade glioma. Histology revealed mixed glial and neuronal elements with low proliferative activity. Standard molecular testing was negative for IDH1/IDH2 and BRAF mutations. DNA methylation profiling did not match to any known CNS class but clustered most closely with low-grade glioma/ganglioglioma. Next-generation RNA sequencing identified a CLIP2::MET fusion as the sole pathogenic alteration. MET fusions are actionable oncogenic drivers across several cancers, and their detection has therapeutic relevance with approved inhibitors. This case expands the spectrum of MET-driven CNS tumors and suggests that CLIP2::MET fusion may represent a distinct molecular subset of glioneuronal tumors relevant to precision oncology.  \nKeywords Glioneuronal tumor, Low-grade glioma, CLIP2::MET, Case report  \n1 Introduction  \nGlioneuronal tumors are uncommon central nervous system (CNS) neoplasms characterized by mixed glial and neuronal differentiation. Their clinical and histological spectrum is wide, and diagnosis can be challenging due to morphologic overlap with other low-grade gliomas and neuronal–glial tumors. Advances in molecular profiling have improved the classification of these tumors, yet their full spectrum of molecular alterations remains incompletely defined [1].  \nReceptor tyrosine kinase fusions, including those involving ALK, ROS1, NTRK, and MET, have emerged as recurrent oncogenic drivers in pediatric and adult gliomas [2, 3]. MET encodes the hepatocyte growth factor receptor (HGFR), a receptor tyrosine kinase that regulates cell proliferation, survival, and motility. Aberrant activation of MET through amplification, mutation, or fusion promotes oncogenic signaling via MAPK and PI3K/AKT pathways, and has been implicated in multiple cancer types [4, 5]. MET alterations, in particular, are implicated in tumor proliferation, invasion, and  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/l](http://creativecommons.org/l)icenses/by-nc-","cbCaijz7yz92DWzy","https://ap.wps.com/l/cbCaijz7yz92DWzy","pdf",1627662,"English","# Abstract\n# 1 Introduction\n## 1.1 Clinical summary","[{\"question\":\"Why is diagnosis of glioneuronal tumors challenging?\",\"answer\":\"Diagnosis and classification are difficult because these tumors show overlapping morphology and often lack defining molecular alterations.\"},{\"question\":\"What molecular finding was identified in this case?\",\"answer\":\"Comprehensive RNA sequencing detected a CLIP2::MET fusion as the sole pathogenic alteration.\"},{\"question\":\"How did methylation and standard testing guide the case classification?\",\"answer\":\"Standard testing was negative for IDH1/IDH2 and BRAF mutations, and DNA methylation profiling did not match known CNS classes, clustering closest to low-grade glioma/ganglioglioma.\"}]","CLIP2::MET fusion identifies a molecularly distinct glioneuronal tumor - Case report | PDF",1790090837,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b6d133afc5c71e76c79a5a6b3a36fb37.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a5d84fb9d61dd93bac85e6a61996f064.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/53132a2fc8cb6948e2ae929cfaa666ee.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/565430991515b4f917f222d948f44dbb.webp",980,1306]